Building pharmacogenetics into a pharmacovigilance program in Singapore: Using serious skin rash as a pilot study

Pharmacogenomics Journal

Volumn 14, Issue 4, 2014, Pages 316-321

  Toh, D S L ^a   Tan, L L ^a   Aw, D C W ^b   Pang, S M ^c   Lim, S H ^c,d   Thirumoorthy, T ^c   Lee, H Y ^c   Tay, Y K ^e,f   Tan, S K ^e   Vasudevan, A ^e   Lateef, A ^b   Chong, Y Y ^c,i   Chan, Y C ^b,f   Loke, C ^a   Chan, C L ^a   Koay, E S C ^b,g   Ren, E C ^h   Lee, E J D ^g   Sung, C ^a,d  

^a HEALTH SCIENCES AUTHORITY   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e CHANGI GENERAL HOSPITAL   (Singapore)

^f Dept Medicine Endocrinol Diabet   (Singapore)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h AGENCY FOR SCIENCE   (Singapore)

ⁱ RAFFLES HOSPITAL   (Singapore)

Author keywords

1502 genotyping; carbamazepine; HLA B; pharmacogenetics; pharmacovigilance; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

CARBAMAZEPINE; HLA B ANTIGEN;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HUMAN; MALE; PHARMACOGENETICS; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; SINGAPORE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ALLELE; CASE CONTROL STUDY; CHEMICALLY INDUCED; GENETICS; MIDDLE AGED; PROCEDURES; RASH; STEVENS-JOHNSON SYNDROME;

ADULT; ALLELES; CARBAMAZEPINE; CASE-CONTROL STUDIES; EXANTHEMA; GENOTYPE; HLA-B ANTIGENS; HUMANS; MIDDLE AGED; PHARMACOGENETICS; PHARMACOVIGILANCE; PILOT PROJECTS; SINGAPORE; STEVENS-JOHNSON SYNDROME;

EID: 84904970728     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.46     Document Type: Article

References (28)

1. Aagaard L, Strandell J, Melskens L, Petersen PSG, Holme Hansen E. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBaset. Drug Saf 2012; 35: 1171-1182.
2. Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C et al. A marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
3. Lonjou C, Thomas L, Borot N, Ledger N, De Toma C, Lelouet H et al. A marker for Stevens-Johnson syndrome ethnicity matters. Pharmacogenomics J 2006; 6: 265-268.
4. Man CBL, Kwan P, Baum L, Yu E, Lau KM, Cheng ASH et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-1018.
5. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49: 2087-2091.
6. Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S. Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007; 143: 367-368.
7. Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther 2011; 89: 896-901.
8. Hung S-I, Chung W-H, Jee S-H, Chen W-C, Chang Y-T, Lee W-R et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
9. Pozzi S, Longo A, Ferrara GB. HLA-B locus sequence-based typing. Tissue Antigens 1999; 53: 275-281.
10. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-1613.
11. van der Zwan AW, Griffith B, Rozemuller E. In: Tilanus MG, Hansen JA, Hurley C (eds). IHWG Technical Manual Genomic Analysis of the Human MHC DNA-Based Typing for HLA Alleles and Linked Polymorphism. International Histocompatibility Working Group: Seattle, 2000, pp TMI14.A12-14.
12. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiute D, Carrington M et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-1143.
13. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20: 1034-1041.
14. Lam TH, Shen MX, Chia JM, Chan SH, Ren EC. Population-specific recombination sites within the human MHC region. Heredity 2013; 111: 131-138.
15. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
16. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
17. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009; 4: e4439.
18. Dave DM, Goyal RK, Joshi CG, Mehta TY, Mittal B, Patel DB. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75: 579-582.
19. Then SM, Rani Z, Raymond A, Ratnaningrum S, Jamal R. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asia Pac J Allergy Immunol 2011; 29: 290-293.
20. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA. Genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012; 92: 757-765.
21. Ko T-M, Chung W-H, Wei C-Y, Shih H-Y, Chen J-K, Lin C-H et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced StevensJohnson syndrome. J Allergy Clin Immunol 2011; 128: 1266-1276.
22. Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012; 79: 1259-1267.
23. Theodore WH, Spencer SS, Wiebe S, Langfitt JT, Ali A, Shafer PO et al. Epilepsy in North America: a report prepared under the auspices of the global campaign against epilepsy, the International Bureau for Epilepsy, the International League Against Epilepsy, and the World Health Organization. Epilepsia 2006; 47: 1700-1722.
24. Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C et al. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemol Drug Saf 2009; 18: 713-721.
25. Molokhia M, McKeigue P. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 2006; 7: 633-638.
26. Holden AL. The innovative use of a large-scale industry biomedical consortia to research the genetic basis of drug induced serious adverse events. Drug Discov Today 2007; 4: 75-85.
27. Pirmohamed M. Pharmacogenetics: past, present and future. Drug Discov Today 2011; 16: 852-861.
28. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related StevensJohnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617-1622.